SEC Comment Letter 0000000000-23-012206 to Prime Medicine, Inc. (PRME) (CIK 0001894562) (PRME)
Prime Medicine, Inc. (PRME) (CIK 0001894562)
Date: Nov. 7, 2023 · CIK: 0001894562 · Accession: 0000000000-23-012206
AI Filing Summary & Sentiment
File numbers found in text: 333-275321
Letter
United States securities and exchange commission logo November 7, 2023 Keith Gottesdiener Chief Executive Officer Prime Medicine, Inc. 21 Erie Street Cambridge, MA 02139 Re:Prime Medicine, Inc. Registration Statement on Form S-3 Filed November 3, 2023 File No. 333-275321 Dear Keith Gottesdiener: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Marishka DeToy
Show Raw Text
United States securities and exchange commission logo
November 7, 2023
Keith Gottesdiener
Chief Executive Officer
Prime Medicine, Inc.
21 Erie Street
Cambridge, MA 02139
Re:Prime Medicine, Inc.
Registration Statement on Form S-3
Filed November 3, 2023
File No. 333-275321
Dear Keith Gottesdiener:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Marishka DeToy